Afficher la couverture 'Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH) | Tao, Y.' en grand format
/5

0 avis

Avelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)

Archive ouverte

Tao, Y. | Auperin, A. | Sun, X. | Sire, C. | Martin, L. | Coutte, Alexandre | Lafond, C. | Miroir, J. | Liem, X. | Rolland, F. | Maillard, A. | Colin-Barailhou, N. | Michel, C. | Thariat, J. | Guigay, J. | Bourhis, J.

Edité par CCSD ; Elsevier -

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, SEP 27-OCT 01, 2019. International audience

Consulter en ligne

Suggestions

Du même auteur

Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Archive ouverte | Bourhis, J. | CCSD

International audience

854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

Archive ouverte | Tao, Y. | CCSD

International audience. BackgroundBased on a potential synergistic effect of anti–PD-L1 avelumab plus cetuximab and RT, this combination was tested in a randomized trial against two standards of care (SOC) in LA-SCC...

Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 ``PembroRad'' randomized trial

Archive ouverte | Bourhis, J. | CCSD

ESMO Virtual Congress, ELECTR NETWORK, SEP 19-OCT 18, 2020. International audience

Chargement des enrichissements...